NeoDynamics AB (publ) receives notification of granted patent on biopsy instrument in China
The expected announcement from the Chinese patent authority means that NeoDynamics´ unique biopsy device with front-loaded needle and integrated trocar, an important component of the NeoNavia® biopsy system is approved. The patent increases the protection of the NeoNavia biopsy system, which further strengthens the competitiveness.“This notice, although expected, is positive for our shareholders as the Chinese market is a large and growing biopsy market and an important part of our global strategy. Together with our other patents, this is a confirmation of our unique technology and a good